OncoMatch/Clinical Trials/NCT06038461
An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors
Is NCT06038461 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies Surufatinib Combined With Temozolomide and S-1 for neuroendocrine tumors.
Treatment: Surufatinib Combined With Temozolomide and S-1 — This is a prospective, open, single-center study evaluating the efficacy and safety of surufatinib Combined With Temozolomide and S-1 as the first-line treatment of advanced neuroendocrine tumors
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Neuroendocrine Tumor
Biomarker criteria
Required: MGMT 0/1+ (0/1+)
advanced MGMT0/1+ (G1, G2 or G3) neuroendocrine tumor
Disease stage
Grade: g1g2g3
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Lab requirements
Blood counts
Adequate hematologic function
Kidney function
Adequate renal function; Urine protein < ++ . If Urine protein ≥ ++ ,the amount of urine protein in 24 hours ≤1.0g
Liver function
Adequate hepatic function
Cardiac function
Adequate heart function
Adequate hepatic, renal, heart, and hematologic functions; Urine protein < ++ . If Urine protein ≥ ++ ,the amount of urine protein in 24 hours ≤1.0g
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06038461 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require MGMT?
Yes, MGMT 0/1+ is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages